Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Summary

This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.

Timeline

Start

2022-03-17

Primary completion

2023-11-19

Completion

2024-02-08

Outcome

Missed primary endpoint

release “prespecified threshold for meaningful clinical activity was not reached” innate-pharma.com ↗

Drugs

Indications